Evidence map›Paper›PMID 26740628›Full record

ArticleThe Journal of biological chemistry2016

The Budding Yeast Ubiquitin Protease Ubp7 Is a Novel Component Involved in S Phase Progression.

Stefanie Böhm, Barnabas Szakal, Benjamin W Herken, Meghan R Sullivan, Michael J Mihalevic, Faiz F Kabbinavar, Dana Branzei, Nathan L Clark, Kara A Bernstein

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Evolution-based screening enables genome-wide prioritization and discovery of DNA repair genes.Proceedings of the National Academy of Sciences of the United States of America · 2019
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Stefanie BöhmFrom the Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15213.
Barnabas Szakalthe Department of Molecular Oncology, Fondazione Istituto Fondazione Italiana per la Ricerca sul Cancro di Oncologia Molecolare, Milan 20139, Italy.
Benjamin W HerkenFrom the Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15213.
Meghan R SullivanFrom the Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15213.
Michael J MihalevicFrom the Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15213.
Faiz F KabbinavarFrom the Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15213.
Dana Branzeithe Department of Molecular Oncology, Fondazione Istituto Fondazione Italiana per la Ricerca sul Cancro di Oncologia Molecolare, Milan 20139, Italy.
Nathan L Clarkthe Department of Computational and Systems Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, and.
Kara A BernsteinFrom the Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15213, karab@pitt.edu.
UPMC Hillman Cancer Center · USUniversity of Pittsburgh · US

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Jessie Nedrow · 1988 to 2026
$158.0M
TrainingU54HG008540 · NHGRI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BAHAR, IVET, BERG, JEREMY M · 2014 to 2018
$12.8M
Replication fork dynamics and repair by Rad51 paralogues after DNA alkylationR01ES024872 · NIEHS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BERNSTEIN, KARA A · 2015 to 2019
$2.4M
Mechanistic insights into the SHU complex and Sgs1 in DNA repair and replicationR00GM088413 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BERNSTEIN, KARA A · 2011 to 2013
$772k
Mechanistic insights into the SHU complex and Sgs1 in DNA repair and replicationK99GM088413 · NIGMS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BERNSTEIN, KARA A · 2009 to 2010
$180k
NCI NIH HHS P30 CA047904NCI NIH HHS P30CA047904NHGRI NIH HHS U54 HG008540NHGRI NIH HHS U54HG008540NIEHS NIH HHS ES024872NIEHS NIH HHS R01 ES024872NIGMS NIH HHS GM088413NIGMS NIH HHS K99 GM088413NIGMS NIH HHS R00 GM088413
6 · The paper itself

Abstract

DNA damage must be repaired in an accurate and timely fashion to preserve genome stability. Cellular mechanisms preventing genome instability are crucial to human health because genome instability is considered a hallmark of cancer. Collectively referred to as the DNA damage response, conserved pathways ensure proper DNA damage recognition and repair. The function of numerous DNA damage response components is fine-tuned by posttranslational modifications, including ubiquitination. This not only involves the enzyme cascade responsible for conjugating ubiquitin to substrates but also requires enzymes that mediate directed removal of ubiquitin. Deubiquitinases remove ubiquitin from substrates to prevent degradation or to mediate signaling functions. The Saccharomyces cerevisiae deubiquitinase Ubp7 has been characterized previously as an endocytic factor. However, here we identify Ubp7 as a novel factor affecting S phase progression after hydroxyurea treatment and demonstrate an evolutionary and genetic interaction of Ubp7 with DNA damage repair pathways of homologous recombination and nucleotide excision repair. We find that deletion of UBP7 sensitizes cells to hydroxyurea and cisplatin and demonstrate that factors that stabilize replication forks are critical under these conditions. Furthermore, ubp7Δ cells exhibit an S phase progression defect upon checkpoint activation by hydroxyurea treatment. ubp7Δ mutants are epistatic to factors involved in histone maintenance and modification, and we find that a subset of Ubp7 is chromatin-associated. In summary, our results suggest that Ubp7 contributes to S phase progression by affecting the chromatin state at replication forks, and we propose histone H2B ubiquitination as a potential substrate of Ubp7.

Indexed as

S PhaseChromatinCisplatinCross-Linking ReagentsDNA RepairDNA ReplicationFungal ProteinsGene DeletionGenomic InstabilityHistonesHydroxyureaMicrobial ViabilityNucleic Acid Synthesis InhibitorsSaccharomycetalesUbiquitin-Specific ProteasesChromatinCisplatinCross-Linking ReagentsFungal ProteinsHistonesHydroxyureaNucleic Acid Synthesis InhibitorsUbiquitin-Specific Proteasesdeubiquitinationdeubiquitylation (deubiquitination)DNA damage responseDNA replicationmolecular evolutionyeast genetics

Identifiers

PMID26740628
PMCPMC4813472
OpenAlexW2239022467

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.